MOONFIRE-VENTURES
Moonfire Ventures is today announcing it has raised $115 million to continue backing Europe’s best early-stage startups. Combining a human and tech approach, Moonfire uses proprietary machine learning models and software across the VC value chain to transform venture, solving founder challenges at scale, with greater knowledge and speed.
Through this Moonfire is embracing the new age of AI that is redefining how tech companies are built, driving further access, efficiency and product quality while revolutionising the startup opportunity for founders.
Moonfire: A tech firm transforming venture
Since its launch in 2020, by former Atomico co-founder Mattias Ljungman, Moonfire has been building the most advanced quantitative VC firm in Europe. A firm that is as much a VC-focused tech startup as it is a VC firm and its VCs are as much investors as they are product managers. The team isn’t using off-the-shelf tools, it’s built custom AI models and a large-scale tech stack from the ground up, allowing it to integrate tech across the full VC value chain, from founder discovery to exit.
It’s a symbiotic, proprietary approach that sees the AI help the investors make better decisions; while the investors and on-hand engineers can directly and continuously improve the AI in response to evolving trends and market shifts. All of which directly benefits founders by enabling its investors to build deeper founder relationships.
Moonfire’s technical power, when combined with the team’s operator experience, is a key draw for founders looking for a partner to help them solve their hardest technical challenges. Such as how to harness the power of AI and machine learning – an opportunity the Moonfire team is uniquely placed to help founders maximise, alongside traditional areas like hiring, go-to-market and fundraising. Such is the impact of its approach, Moonfire believes it represents the future of VC by enabling its team to be more impactful, more productive, and drive more value for its founders. A key step in the rise of the 10x VC.
Maths with words
Having defined this approach with Fund I, Moonfire is taking it to the next level with Fund II.
Moonfire now reviews up to 50,000 companies every week – more than 600 times the average of a traditional VC – in search of the very best founding teams in Europe using next-level technologies like AI, Web3, and AR/VR to transform four key sectors – health, work, finance and gaming. Moonfire describes this focus as “where sources of disruption intersect with sectors that are driving innovation” and believes this is key in the pursuit of a more accessible, sustainable and equitable society.
Such is the importance of this thesis, it forms the basis of Moonfire’s AI company evaluation and is the worldview upon which its algorithms model themselves. Using this mathematical representation of its written thesis, Moonfire’s AI is able to discover companies and founders that align with this unique worldview. It empowers investors to make better decisions, faster; it makes VC more inclusive: finding overlooked talent early, more frequently, and with greater accuracy.
Moonfire’s investment into UK Fintech LiveFlow is an example of its tech-first approach in action. Having sourced LiveFlow through its AI engine, Moonfire led the Pre-Seed round alongside Seedcamp and then used the Moonfire team’s technical expertise to build a recruitment funnel that empowered LiveFlow to hire a new, highly experienced CTO. LiveFlow went on to raise a $4 million Seed round, at more than double its initial pre-Seed valuation.
Moonfire Ventures’ Managing Partner Mattias Ljungman said:
“We are entering a new decade of AI that is transforming the possibilities of technology and redefining how tech companies are built through greater access, efficiency and product quality. We want to be there for the founders at the earliest stages powering their growth and being true partners from the very beginning. Europe has been a leader in AI and we find our best fit is to support the next generation of founders solving some of our greatest challenges within health, work, finance and gaming."
Building on success
Ljungman founded Moonfire using insight from 20+ years investing in tech leaders, from Klarna ($6.5bn) to Supercell ($10bn). Partner Mike Arpaia is a computer scientist focused on AI and quantitative finance. He was previously co-founder and CTO of security platform Kolide, and formerly tech lead at Facebook, Etsy, and Workday. Joining Ljungman and Arpaia is a team of entrepreneurs and technologists, 90% of whom have founded and scaled companies themselves.
To date, the Moonfire team has led 23 deals and co-invested in a further 27 with top-tier investors Sequoia, Accel, Index, General Catalyst and Accel since having joined its founders' journeys. Notable successes from Fund I include portfolio company Humaans recently raising a $15m Series A round, Lightdash completing a $7M round led by Accel, and GOALS closing a $20m Series A round with Seven Seven Six. In addition to its $90M Fund II, the firm has raised $25M to double down on its winners via its Opportunity Fund.
Moonfire Ventures partner and computer scientist Mike Arpaia said:
“The power of the AI and VC partnership has always been at the core of Moonfire and, with the launch of Fund II, we see it move to the next level. This new level combines human and machine like never before, hoping to turn an inefficient and inequitable industry on its head. With AI solving the mental-manual work, we can focus on the aspects humans are better at – meeting and forming relationships with founders.”
– ENDS –
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
